- Home
- DNLI vs EWTX Comparison
DNLI vs EWTX Comparison
Compare DNLI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | EWTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DNLI | EWTX |
|---|---|---|
| Price | $22.90 | $40.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $34.33 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $408.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.58 | $12.31 |
| 52 Week High | $27.30 | $48.40 |
Technical Indicators
Market Signals| Indicator | DNLI | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 51.88 |
| Support Level | $18.27 | $29.03 |
| Resistance Level | $23.27 | $43.93 |
| Average True Range (ATR) | 1.39 | 2.68 |
| MACD | -0.45 | -0.26 |
| Stochastic Oscillator | 17.39 | 22.26 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.